Malignancy in patients with sickle cell disease.

摘要: Malignancy in patients with sickle cell disease (SCD) has been previously reported, but the types of cancer and its incidence remain undefined. With advent hydroxyurea therapy, there is concern about increasing risk for SCD. The International Association Sickle Cell Nurses Physician Assistants identified 52 cases (49 patients) among 16,613 SCD followed at institutions. median age malignancy diagnosis was 34 years (range, 14 months-62 years). Twenty-one (40%) occurred pediatric patients, primarily leukemia (n = 7) or Wilms' tumor 5), 15 children surviving. Most adults had solid tumors, especially carcinomas, only nine were known to be alive. Three received before malignancy. These data provide essential baseline information accurate interpretation future reports SCD, those receiving therapy.